Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
|Loading, please wait...|
BIIB News Highlights
- For BIIB, its 30 day story count is now at 65.
- Over the past 25 days, BIIB's stories per day has been in a clear downtrend, falling by about 0.32 per day.
- The most mentioned tickers in articles about BIIB are MS, AGE and AMD.
Latest BIIB News From Around the Web
Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months. The consensus price target for Bristol Myers Squibb (NYSE: BMY) is 39% above the big drugmaker's current share price. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In September 2020, Biogen launched a a 20-year, $250m commitment to eliminate fossil fuel emissions from its operations by 2040 and advance action on the deeply interconnected challenges of climate...
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower risk of relapse for patients treated with TYSABRI® compared to Ocrevus® (ocrelizumab)New data from EVOLVE-MS-2 demonstrate that a favorable gastrointestinal (GI) tolerability profile for VUMERITY® (diroximel fumarate) is achieved and maintained with dose titration CAMBRIDGE, Mass., Oct. 13, 202
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest that approximately 40 percent of people with MS treated with anti-CD20 and S1P disease-modifying therapies (DMT) mount an antibody response to the COVID-19 vaccineCollaborative MS PATHS network enabled rapid collection of data in the COVID-19 environment CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE
The following are three healthcare stocks that may do just that. Wall Street predicts they could rise more than 40% in the coming 12 months. Teladoc Health (NYSE: TDOC) shares have slipped more than 18% over the past three months.
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Each week Trifecta Stocks identifies names that look bearish and may present interesting investing opportunities on the short side. Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on five names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.